WINLEVI® (clascoterone)

LOCALLY REDUCE SEBUM PRODUCTION1

Adverse events should be reported.

Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to Glenmark Pharmaceuticals Europe Ltd

medical_information@glenmarkpharma.com or call 0800 458 0383.

1. Rosette C, et al. J Drugs Dermatol. 2019;18(5):412-418.

FIRST-IN-CLASS, INNOVATIVE TOPICAL ANDROGEN-RECEPTOR INHIBITOR1

  • WINLEVI® (clascoterone) 10 mg/g cream is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.2

  • WINLEVI® is the ONLY topical anti-androgen specifically developed to locally reduce sebum.1

  • WINLEVI® is the FIRST androgen-receptor inhibitor appropriate for use in both FEMALE and MALE acne patients (12 years of age and older).2,3

1. Rosette C, et al. J Drugs Dermatol. 2019;18(5):412-418.
2. WINLEVI® SPC.
3. Eichenfield LF, et al. J Drugs Dermatol. 2024;23(1):1278-1283.

Explore more
For market research purposes only